Table II.
Treatment prior to the administration of nanoparticle albumin-bound-PTX plus carboplatin therapy.
| Regimen | 1st line | 2nd line | 3rd line | 4th line | 5th line or later |
|---|---|---|---|---|---|
| S-1+platinum | 8 | 0 | 0 | 0 | 0 |
| BEV+PEM+platinum | 7 | 3 | 0 | 0 | 0 |
| PEM+platinum | 4 | 1 | 0 | 0 | 0 |
| PTX+platinum | 2 | 0 | 0 | 0 | 0 |
| GEM+platinum | 1 | 1 | 0 | 0 | 0 |
| EGFR-TKI | 2 | 4 | 1 | 0 | 4 |
| Single DOC | 0 | 4 | 1 | 0 | 0 |
| Others | 1 | 0 | 0 | 2 | 4 |
S-1, tagafur/gimeracil/oteracil; BEV, bevacizumab; PEM, pemetrexed; PTX, paclitaxel; GEM, gemcitabine; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; DOC, docetaxel.